Pegylated megakaryocyte growth and development factor data

Researchers presented positive results from two Phase I/II studies at the American Society of Clinical Oncology meeting in Philadelphia. AMGN has treated more than 180 patients with PEG-MGDF, with results from the first two studies showing that the compound decreased the duration of thrombocytopenia caused by chemotherapy. MGDF was well-tolerated at all doses.

In a U.S. study of 50 lung cancer patients who received carboplatin and paclitaxel followed by MGDF or placebo, MGDF decreased the duration and severity of thrombocytopenia. Cohorts of four patients received 0.03, 0.1, 0.3, 1, 3 or 5 µg/kg/day. ...